| Background:Coronary atherosclerotic heart disease (CHD),a common and frequently-occurring disease, is a kind of common disease endangering the human health seriously.Coronary atherosclerosis, narrowing or obstructing the vessel lumen, causes the coronary microcirculation dysfunction, which leads to the cardiac muscle to be short of blood, anoxic and then suffers from a acute heart attack.In recent years, a large number of the studies of vulnerable plaques found that histologic features in plaques is the more important indicator to reflect prognosis than its size. Vulnerablity and thrombophilia of plaque will be more precise whether acute cardiac events occur, compared with the degree of stenosis and its size. Vulnerable plaques has the following features with thin fibrous cap,big size lipid core and more inflammatory cells, such as macrophage infiltration.The current view is that atherosclerosis is a dynamic and progressive process with interaction between endothelial dysfunction and an inflammatory response. Therefore,In the second degree prevention of CHD, researchs focus on the rupture mechanism of unstable coronary atherosclerotic plaque, vulnerable plaques prediction,and stabilization atherosclerosis plaques, which owns the most important clinical significance and great value.Objective:To observe the effect of Shan-zha-xiao-zhi Capsule on the stability of vulnerable plaques in non-acute phase CHD patients with phlegm and blood stasis type; Provide theoretical basis for its clinical application by Exploring its mechanism of Shan-zha-xiao-zhi Capsule on the stability of vulnerable plaques.Methods:①68 cases of CHD patients, admitted to outpatient or hospital patients of the Foshan Hospital of TCM from May 2010 to January 2011, were randomly divided into treatment group(33 cases) and control group(35 cases); ②Before treatment and 28 days after treatment, Cholesterol, Triglyceride, High density lipoprotein, low density lipoprotein were detected with biochemistry analyzer made in USA;③Standards of grading of Blood Stasis accords to Chen Ke Yi's and (the Chinese herbal medicine new medicine clinic research guideline), Phlegm Stasis refers to Fang Yong Qi (Quantification Research of phlegm macro-identification on caradio-cerebero vascular disease);④Before treatment, after 28-day and in First 24 Hours after acute heart attack, the expression of ox-LDL, MMP-9, hs-CRP in two groups were respectively detect by ELISA, ELISA, particle-enhanced immunonelometry.Results:①Aafter treatment, the difference of clinical curative effect between the two groups of patients was statistical significance (Mean ridit=0.4310, P=0.3130> 0.05), but the overall efficacy rate of Shan-zha-xiao-zhi Capsule (93.59%) is slightly Higher than Xue-zhi-kang Capsule (86.67%).②Phlegm and blood stasis scores in two groups of CHD patients ware obviously high,but the difference between two groups owned no statistical significance(*P=0.1721,#P=0.2813);after treatment, Phlegm and blood stasis scores in two groups of CHD patients had decreased obviously, but the treatment group's dropped more significantly than the control group, the difference owned statistical significant (*P=0.0150,#P=0.008)③Before treatment, the level of Total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL)-C), high-density lipoprotein cholesterol (HDL-C) between two groups ware significantly higher than normal reference caps, the difference had no statistical significance(P> 0.05).④the level of ox-LDL, hs-CRP, MMP-9 in two groups of coronary heart disease patients is obviously higher than normal reference caps, and the difference between two groups owned statistical significance(P<0.05);After treatment,comparison of the level of ox-LDL, hs-CRP, MMP-9 between the two groups had statistical significance(P<0.05).⑤after acute cardiovascular events, Phlegm and blood stasis scores, the level of ox-LDL, hs-CRP, MMP-9 had Increased significantly。 ⑥The difference of acute cardiovascular events between two groups of coronary artery disease patients had no statistical significance(P> 0.05), the rare of acute cardioascular events was also no statistical signif icance (P> 0.05).Conclusions:Shan-zha-xiao-zhi Capsule is an effective preparation to treat the CHD, which can significantly improve clinical symptoms of patients with coronary artery disease; Shan-zha-xiao-zhi Capsule can obviously decrease the incidence of acute cardiovascular events, The mechanism may be positively correlated with reduction of the ox-LDL, hs-CRP, MMP-9 level, Shan-zha-xiao-zhi Capsule can relieve inflammatory reaction of atherosclerostic plaques from reduction of the ox-LDL, hs-CRP, MMP-9 level.
|
PDF Full Text Request